OOIR: Observatory of International Research

Papers

(The TQCC of Pharmacogenomics is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Clinical implementation of pharmacogenomics via a health system-wide research biobank: the University of Colorado experience	39
Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine?	31
Differences in telomere length between patients with bipolar disorder and controls are influenced by lithium treatment	27
Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy	25
Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry	25
Assessment of primary care practitioners’ attitudes and interest in pharmacogenomic testing	22
The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis	22
Precision medicine in interventional cardiology: implications for antiplatelet therapy in patients undergoing percutaneous coronary intervention	21
The inclusion of health data standards in the implementation of pharmacogenomics systems: a scoping review	21
PARC report: a health-systems focus on reimbursement and patient access to pharmacogenomics testing	21
Potential of whole-genome sequencing-based pharmacogenetic profiling	18
Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study	18
Cost–effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective	18
Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors	17
Strategies and settings of clinical pharmacogenetic implementation: a scoping review of pharmacogenetics programs	17
PGxKnow: a pharmacogenomics educational HoloLens application of augmented reality and artificial intelligence	16
Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program	16
Cost avoidance related to a pharmacist-led pharmacogenomics service for the Program of All-inclusive Care for the Elderly	16
Pharmacogenomics in the UK National Health Service: opportunities and challenges	15
Pharmacogenomics of methadone: a narrative review of the literature	14
Pharmacogenomic testing to support prescribing in primary care: a structured review of implementation models	14
Effects of the CYP2C19 LoF allele on major adverse cardiovascular events associated with clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-an	14
NUDT15 genetic variants are related to thiopurine-induced neutropenia in Thai children with acute lymphoblastic leukemia	14
Pharmacogenomics of oxycodone: a narrative literature review	14
Genetic susceptibilities and prediction modeling of carbamazepine and allopurinol-induced severe cutaneous adverse reactions in Vietnamese	14

ATP binding cassette transporters and cancer: revisiting their controversial role	13
CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls	13
Providers’ perspectives on the clinical utility of pharmacogenomic testing in pediatric patients	12
Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics	11
Pharmacotherapies and personalized medicine for alcohol use disorder: a review	11
ACE2 and COVID-19: using antihypertensive medications and pharmacogenetic considerations	11
An assessment of patient perspectives on pharmacogenomics educational materials	11
The pharmacogenetics of treatment with olanzapine	11
Pharmacogenomics education, research and clinical implementation in the state of Minnesota	11
Resolving discordant CYP2D6 genotyping results in Thai subjects: platform limitations and novel haplotypes	10
Developing a gene panel for pharmacoresistant epilepsy: a review of epilepsy pharmacogenetics	10
The effect of CYP2C19 gene polymorphism on the eradication rate of Helicobacter pylori by proton pump inhibitors-containing regimens in Asian populations: a meta-analysis	10
Evaluating the current level of pharmacists’ pharmacogenomics knowledge and its impact on pharmacogenomics implementation	10
Substrate specificity of CYP2D6 genetic variants	9
Effect of UGT polymorphisms on pharmacokinetics and adverse reactions of mycophenolic acid in kidney transplant patients	9
Variant discovery using next-generation sequencing and its future role in pharmacogenetics	9
Pharmacogenomics in psychiatry – the challenge of cytochrome P450 enzyme phenoconversion and solutions to assist precision dosing	9
lncRNA MALAT1 regulates the resistance of breast cancer cells to paclitaxel via the miR-497-5p/SHOC2 axis	9
Impact of variants in ATP-binding cassette transporters on breast cancer treatment	9
PARC report: a perspective on the state of clinical pharmacogenomics testing	8
Pharmacogenetics of inflammatory bowel disease	8
Pharmacogenetics of anxiety and depression in Alzheimer's disease	8
The effects of sex on pharmacogenetically guided drug treatment	8
Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy	8
Challenges in pharmacotherapy for older adults: a framework for pharmacogenomics implementation	8
MTHFR, TYMS and SLCO1B1 polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis	8
Involvement of CYP2D6 and CYP2B6 on tramadol pharmacokinetics	8
Nonresponse to high-dose bupropion for depression in a patient carrying CYP2B66 and CYP2C19**17 variants: a case report	8
Understanding the barriers and enablers of pharmacogenomic testing in primary care: a qualitative systematic review with meta-aggregation synthesis	8
Gender-dependent association ofTYMS-TSER polymorphism with 5-fluorouracil or capecitabine-based chemotherapy toxicity	8
Exploring pharmacogenetic variants for predicting response to anti-TNF therapy in autoimmune diseases: a meta-analysis	8
HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium	8
Liquid biopsy for the detection of clinical biomarkers in early breast cancer: new insights and challenges	7
Patients’ perspectives of a pharmacist-provided clinical pharmacogenomics service	7
NAMPTsingle-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia	7
Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients	7
Effects of SLCO1B1 on elimination and toxicities of high-dose methotrexate in pediatric acute lymphoblastic leukemia	7
miRNAs as potential biomarkers of treatment outcome in rheumatoid arthritis and ankylosing spondylitis	7
Association of NAT-2 gene polymorphisms toward lung cancer susceptibility and prognosis in North Indian patients treated with platinum-based chemotherapy	7
PARC report: health outcomes and value of personalized medicine interventions: impact on patient care	7
Immunotherapy in non-small-cell lung cancer: from targeted molecules to resistance patterns	7
Synthesis of major pharmacogenomics pretest counseling themes: a multisite comparison	7
The need to shift pharmacogenetic research from candidate gene to genome-wide association studies	7
The pharmacogenetics of aripiprazole-induced hyperprolactinemia: what do we know?	6
Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews	6
The importance of phenoconversion when using the CYP2D6 genotype in clinical practice	6
HLA-DRB1*16:02 is associated with PEG-asparaginase hypersensitivity	6
Resistance to platinum-based cancer drugs: a special focus on epigenetic mechanisms	6
Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population	6
Malignant hyperthermia susceptibility: utilization of genetic results in an electronic medical record to increase safety	6

The influence of coffee intake and genetics on adenosine pathway in rheumatoid arthritis	6
Genetic characterization of N-acetyltransferase 2 variants in acquired multidrug-resistant tuberculosis in Indonesia	6
Genetic variation in Charcot–Marie–Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy	6
The promise of digital health in healthcare equity and medication adherence in the disadvantaged dementia population	6
Interethnic differences in the prevalence of main cardiovascular pharmacogenetic biomarkers	6
The frequency of rs2231142 in ABCG2 among Native Hawaiian and Pacific Islander subgroups: implications for personalized rosuvastatin dosing	6
Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes	6
Polymorphisms in theCYP3A5gene significantly affect the pharmacokinetics of sirolimus after kidney transplantation	6
Personal genotyping and student outcomes in genetic and pharmacogenetic teaching: a systematic review and meta-analysis	6
Efficacy and safety of opioid therapy guided by pharmacogenetics: a systematic review	6
The association betweenHLA-B*15:02and phenytoin-induced severe cutaneous adverse reactions: a meta-analysis	6
Noncoding SNPs associated with increased GDF15 levels located in a metformin-activated enhancer region upstream of GDF15	6
Clinical and genetic predictors of secondary sulfonylurea failure in Type 2 diabetes patients: the SUCLINGEN study	6
Progression of precision statin prescribing for reduction of statin-associated muscle symptoms	6
Adolescent perceptions of pharmacogenetic testing	6
Genome-wide association study of liver enzyme elevation in rheumatoid arthritis patients starting methotrexate	6
Synonymous mutation rs2515641 affects CYP2E1 mRNA and protein expression and susceptibility to drug-induced liver injury	6
Association between genetic variants and the risk of nivolumab-induced immune-related adverse events	5
Genome-wide association study of liver enzyme elevation in an extended cohort of rheumatoid arthritis patients starting low-dose methotrexate	5
Pharmacogenetic loci for rosuvastatin are associated with intima-media thickness change and coronary artery disease risk	5
CYP2D6 pharmacogenetics and risperidone: reflections after 25 years of research	5
The revolution of pharmaco-omics: ready to open new avenues in materializing precision medicine?	5
Implementation of a pharmacogenomic program in a Brazilian public institution	5
Integrating pharmacogenetic testing via medication therapy management in an outpatient family medicine clinic	5
Predictive association of ABCB1 C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients	5
Nimodipine-induced junctional bradycardia in an elderly patient with subarachnoid hemorrhage	5
Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?	5
Pharmacogenomics education and perceptions: is there a gap between internal medicine resident and attending physicians?	5
Engaging pharmacogenomics in pain management and opioid selection	5
Healthcare professionals' knowledge, confidence and perceptions of pharmacogenomics in primary care and pain management	5
Pharmacogenomics and prescription opioid use	5
Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites	5
DPYDgenotyping and predicting fluoropyrimidine toxicity: where do we stand?	5
KRAS-targeted therapies in advanced solid cancers: drug the undruggable?	5
Poly-(ADP-ribose) polymerase inhibitors: paradigm shift in the first-line treatment of newly diagnosed advanced ovarian cancer	5
Pharmacogenetic differentiation across Latin America	5
Pharmacogenomics in clinical practice to prevent risperidone-induced hyperprolactinemia in autism spectrum disorder	5
Methods for actionable gene fusion detection in lung cancer: now and in the future	5
Unraveling heterogeneity of the clinical pharmacogenomic guidelines in oncology practice among major regulatory bodies	5
Clinical utility of pharmacogenetic testing in the treatment of bipolar disorder of Chinese patients	5
Brazilian cohort and genes encoding for drug-metabolizing enzymes and drug transporters	5
Pharmacogenetic evaluation of 6-mercaptopurine-mediated toxicity in pediatric acute lymphoblastic leukemia patients from a South Indian population	5
A meta-analysis of effects of CYP2C9 and CYP2C19 polymorphisms on phenytoin pharmacokinetic parameters	5
PNPT1 and PCGF3 variants associated with angiotensin-converting enzyme inhibitor-induced cough: a nested case–control genome-wide study	5